For your T1D patients 1 year or older,
Dose timing and other reasons to consider Tresiba® (insulin degludec)
For adults with T1D, if life gets in the way of a scheduled dose
Tresiba® provides continued efficacy
JC takes his basal injection daily before work but sleeps in on weekends. On those days, he doesn’t know when he will dose.
Tresiba®, a formulation of insulin degludec, is the only basal insulin that gives adult patients the option to change dose timing day to day, if needed.1-5
- Adult patients who miss a dose of Tresiba® should inject their daily dose during waking hours upon discovering the missed dose, then continue with their regular dosing schedule1
- Ensure that at least 8 hours have elapsed between Tresiba® injections1
As demonstrated in the BEGIN clinical trial program
Tresiba® provides proven A1C reduction1
Tresiba® efficacy and safety were studied in adult and pediatric patients with T1D. And the SWITCH 1 trial further evaluated the safety profile of Tresiba® in adult patients with T1D at increased risk of hypoglycemia.1,6
All pictures and scenarios are for illustrative purposes only.
Have patients with T1D who face challenges with dose timing at mealtimes?
Consider a bolus insulin with mealtime dosing flexibility to improve glycemic control in adult and pediatric patients with diabetes.7
Tresiba® FlexTouch® is a prefilled insulin pen with no push-button extension
Standard insulin pen
Tresiba® FlexTouch® U-100
No matter what dose is dialed, the Tresiba® FlexTouch® U‑100 push button doesn’t extend any higher.
Contains 300 total units
Maximum dose of 80 units in a single injection
1-unit dose increments
After opening, Tresiba® may be used for up to 8 weeks when kept at room temperature or in the refrigerator vs 4 weeks for insulin glargine U-100.1,2,a,b
aOpened (in-use) Tresiba® should be refrigerated (36°F to 46°F [2°C to 8°C]) or kept at room temperature (up to 86°F [30°C]), away from direct heat and light.1
bOpened (in-use) Lantus® SoloSTAR® device must be discarded 4 weeks after being opened. Once in use, the device must be kept at room temperature.2
An additional option for patients who prefer vials1
- Contains 1000 total units
- Option for children who need half-unit increments
Once in use, the Tresiba® vial lasts 8 weeks, 2X as long as the insulin glargine U-100 vial, and 2 weeks longer than the insulin detemir vial.1-3,c,d
cIn-use Tresiba® can be kept at room temperature (up to 86°F), away from direct heat and light, or refrigerated (36°F-46°F).
dThe in-use insulin glargine U-100 vial must be discarded after 4 weeks and the in-use insulin detemir vial must be discarded after 6 weeks.2,3
When starting a patient with T1D on a basal insulin
Commercially insured patients can save on Tresiba®
Eligible patients may pay as little as $35 or no more than $99 per prescription of Tresiba®e
Direct your patients to TresibaSavings.com
These trusted partners are helping young patients with type 1 diabetes
Starting adults on Tresiba®
Starting pediatric patients (≥1 year of age) on Tresiba®
Indications and Usage for Tresiba® (insulin degludec) injection 100 U/mL, 200 U/mL
Tresiba® (insulin degludec) injection is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.
Limitations of Use
Tresiba® is not recommended for treating diabetic ketoacidosis.
Important Safety Information
Contraindications
- Tresiba® is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to insulin degludec or any of the excipients in Tresiba®
Warnings and Precautions
- Never Share a Tresiba® FlexTouch® Pen, Needle, or Syringe Between Patients, even if the needle is changed. Patients using Tresiba® vials should never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens.
- Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Changes in an insulin regimen (e.g., insulin strength, manufacturer, type, or injection site or method of administration) may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis have been reported to result in hyperglycemia; and a sudden change in the injection site (to an unaffected area) has been reported to result in hypoglycemia. Make any changes to a patient’s insulin regimen under close medical supervision with increased frequency of blood glucose monitoring. Advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor for hypoglycemia. Adjustments in concomitant anti-diabetic treatment may be needed.
- Hypoglycemia: Hypoglycemia is the most common adverse reaction of insulin, including Tresiba®. Severe hypoglycemia can cause seizures, may be life-threatening or cause death. Hypoglycemia can impair concentration ability and reaction time; this may place the patient and others at risk in situations where these abilities are important (e.g., driving or operating other machinery). Hypoglycemia can happen suddenly and symptoms may differ in each patient and change over time in the same patient. Symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes, in patients with diabetic neuropathy, using drugs that block the sympathetic nervous system (e.g., beta-blockers) or who experience recurrent hypoglycemia. The long-acting effect of Tresiba® may delay recovery from hypoglycemia compared to shorter-acting insulins.
Risk Factors for Hypoglycemia: The risk of hypoglycemia generally increases with intensity of glycemic control. The risk of hypoglycemia after an injection is related to the duration of action of the insulin and, in general, is highest when the glucose lowering effect of the insulin is maximal. As with all insulins, the glucose lowering effect time course of Tresiba® may vary among different patients or at different times in the same patients and depends on many conditions, including the area of injection as well as the injection site blood supply and temperature. Other factors which may increase the risk of hypoglycemia include changes in meal pattern, changes in level of physical activity, or changes to concomitant drugs. Patients with renal or hepatic impairment may be at higher risk of hypoglycemia. Patients and caregivers must be educated to recognize and manage hypoglycemia. In patients at higher risk for hypoglycemia and patients who have reduced symptomatic awareness of hypoglycemia, increased frequency of blood glucose monitoring is recommended. - Hypoglycemia Due to Medication Errors: Accidental mix-ups between insulin products have been reported. To avoid medication errors between Tresiba® and other insulins, always instruct patients to always check the insulin label before each injection. To avoid dosing errors and potential overdose, never use a syringe to remove Tresiba® from the Tresiba® FlexTouch® disposable insulin prefilled pen.
- Hypersensitivity Reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulins, including Tresiba®. If hypersensitivity reactions occur, discontinue Tresiba®; treat per standard of care and monitor until symptoms and signs resolve.
- Hypokalemia: All insulins, including Tresiba®, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia and treat if indicated.
- Fluid Retention and Heart Failure with Concomitant Use of PPAR-gamma Agonists: Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including Tresiba®. Patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of the TZD must be considered.
Adverse Reactions
- Adverse reactions commonly associated with Tresiba® are hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema, and weight gain.
Drug Interactions
- There are certain drugs that may cause clinically significant drug interactions with Tresiba®.
- Drugs that may increase the risk of hypoglycemia: antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors
- Drugs that may decrease the blood glucose lowering effect: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones
- Drugs that may increase or decrease the blood glucose lowering effect: alcohol, beta-blockers, clonidine, lithium salts, and pentamidine
- Drugs that may blunt the signs and symptoms of hypoglycemia: beta-blockers, clonidine, guanethidine, and reserpine
Please click here for Tresiba® Prescribing Information.
References:
- Tresiba [package insert]. Plainsboro, NJ: Novo Nordisk Inc; July 2022.
- Lantus [package insert]. Bridgewater, NJ: sanofi-aventis US LLC; June 2022.
- Levemir [package insert]. Plainsboro, NJ: Novo Nordisk Inc; December 2022.
- Toujeo [package insert]. Bridgewater, NJ: sanofi-aventis US LLC; August 2022.
- Basaglar [package insert]. Indianapolis, IN: Lilly USA LLC; July 2021.
- Lane W, Bailey TS, Gerety G, et al. JAMA. 2017;318(1):33-44.
- Fiasp [package insert]. Plainsboro, NJ: Novo Nordisk Inc; September 2022.